AMGN - Amgen Inc.
| Previous Close | 179.54 |
| Open | 180.67 |
| Bid | 175.72 x 4000 |
| Ask | 181.97 x 900 |
| Day's Range | 178.20 - 181.54 |
| 52 Week Range | 166.30 - 210.19 |
| Volume | 2,987,154 |
| Avg. Volume | 2,831,947 |
| Market Cap | 108.806B |
| Beta (3Y Monthly) | 0.95 |
| PE Ratio (TTM) | 14.23 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 5.80 (3.25%) |
| Ex-Dividend Date | 2019-05-16 |
| 1y Target Est | N/A |
- Investor's Business Daily•4 days ago
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
Gilead Sciences should acquire Celgene's psoriasis drug Otezla, but only for less than $9.6 billion, analysts said Thursday. Celgene is divesting Otezla ahead of its Bristol-Myers merger.
- Zacks•5 days ago
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
Key highlights of the past week include collaborations and other pipeline updates.
- American City Business Journals•6 days ago
Eisai boosts focus on Alzheimer's with new research facility, funding
Japanese drugmaker Eisai is investing $120 million over three years in an Alzheimer's research center — a 20 percent increase over the funding Eisai originally had allocated for the facility.
- Zacks•6 days ago
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Motley Fool•10 days ago
What Happened in the Stock Market Today
On a record day for the major benchmarks, Illumina issued a warning, and Novartis and Amgen reported the failure of an Alzheimer's drug.
- Zacks•10 days ago
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
- Zacks•10 days ago
Amgen & Novartis' Alzheimer Studies End in Another Failure
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.
- Benzinga•10 days ago
Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug
A drug to treat Alzheimer's disease is increasingly proving elusive, despite billions of dollars spent on research and development. Johnson & Johnson (NYSE: JNJ )'s Janssen unit; Merck & Co., Inc. (NYSE: ...
- Zacks•10 days ago
Why Amgen (AMGN) Could Beat Earnings Estimates Again
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Investor's Business Daily•10 days ago
Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails
Dow Jones futures: Illumina stock and profitable marijuana stock Innovative Industrial Properties fell late on news. An Amgen-Novartis Alzheimer's drug failed. Hookipa Pharma soared.
- Benzinga•10 days ago
The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on July 11) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) GALAPAGOS ...
- Zacks•10 days ago
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
Style Box ETF report for FLQL
- MarketWatch•11 days ago
Amgen and Novartis drop Alzheimer's-prevention study after patients worsened
Amgen Inc. and Novartis AG announced Thursday afternoon that they will discontinue a study into a potential Alzheimer's disease prevention therapy after patients in the study showed worsening conditions. "An assessment of unblinded data during a regular pre-planned review identified worsening in some measures of cognitive function," the companies said in a joint announcement. "The sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk." The phase 2/3 study, performed in conjunction with Banner Alzheimer's Institute, was testing the BACE1 inhibitor CNP520, or umibecestat, which is an amyloid-focused drug. Biogen Inc. failed in testing of an amyloid-focused drug earlier this year, leading some to predict that focusing on the sticky protein found in the brain could be a losing route to a drug for the debilitating neurodegenerative disease. "We still believe amyloid plays an important but complex role in Alzheimer's disease," Amgen executive David Reese said in Thursday's announcement. Novartis shares were down 1.5% in after-hours trading Thursday, while Amgen shares were not moving after the announcement.
- Yahoo Finance•11 days ago
Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates
The drug companies provide rebates to PBMs in exchange for distributing their products.
- Zacks•11 days ago
Trump's Order on Kidney Care Lifts These Dialysis Stocks
Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.
- Investing.com•11 days ago
Amgen Falls 3%
Investing.com - Amgen (NASDAQ:AMGN) fell by 3.30% to trade at $176.27 by 10:44 (14:44 GMT) on Thursday on the NASDAQ exchange.
- Financial Times•11 days ago
Amgen, Novartis abandon two Alzheimer’s drug studies
Amgen and Novartis have closed two studies trying to find drugs for Alzheimer’s disease, dealing another blow to the millions of patients left waiting for a treatment for the neurodegenerative disorder. The pharmaceutical companies, along with their partner, the research centre Banner Alzheimer’s Institute, said that some patients on the trials had shown a worsening — rather than the hoped for improvement — in cognitive function. The decision comes after Biogen, a neuroscience-focused biotech company, closed down its Alzheimer’s drug trial with Japanese company Eisai in April, after they found the drug was not going to be effective.
- Zacks•12 days ago
Mirati Inks Deal with Novartis to Evaluate Tumor Candidate
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
- Motley Fool•12 days ago
The 10 Biggest Healthcare Stocks
How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.
- Zacks•12 days ago
Court Ruling Topples Trump Order, No Price Display in TV Ads
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
- Zacks•12 days ago
Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA
FDA accepts Merck's (MRK) sBLAs for a six-week dosing schedule of Keytruda for melanoma and multiple other indications
- Zacks•12 days ago
Will Patent Woes Boost Pharma Stock Megamergers Further?
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
- Zacks•13 days ago
Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline
Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.
- GuruFocus.com•13 days ago
Political Football Stocks
A discussion of the tribulation arising out of political scrutiny and the sectors or companies suffering at the hands of political football
- Barrons.com•13 days ago
Merck, Amgen, and Eli Lilly Get a Drug Pricing Win in Court
A federal judge handed a big win to big pharma on Monday, saying a regulation that required drug companies to disclose drug prices in television ads was invalid.
